- Home
- EXEL vs SIGA Comparison
EXEL vs SIGA Comparison
Compare EXEL & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- SIGA
- Stock Information
- Founded
- EXEL 1994
- SIGA 1995
- Country
- EXEL United States
- SIGA United States
- Employees
- EXEL N/A
- SIGA N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- EXEL Health Care
- SIGA Health Care
- Exchange
- EXEL Nasdaq
- SIGA Nasdaq
- Market Cap
- EXEL 10.4B
- SIGA 515.1M
- IPO Year
- EXEL 2000
- SIGA 1997
- Fundamental
- Price
- EXEL $39.01
- SIGA $9.00
- Analyst Decision
- EXEL Buy
- SIGA
- Analyst Count
- EXEL 21
- SIGA 0
- Target Price
- EXEL $43.65
- SIGA N/A
- AVG Volume (30 Days)
- EXEL 2.3M
- SIGA 513.2K
- Earning Date
- EXEL 10-28-2025
- SIGA 11-06-2025
- Dividend Yield
- EXEL N/A
- SIGA 6.67%
- EPS Growth
- EXEL 81.76
- SIGA N/A
- EPS
- EXEL 2.08
- SIGA 1.14
- Revenue
- EXEL $2,230,005,000.00
- SIGA $179,639,422.00
- Revenue This Year
- EXEL $9.24
- SIGA N/A
- Revenue Next Year
- EXEL $13.04
- SIGA $115.06
- P/E Ratio
- EXEL $18.72
- SIGA $7.89
- Revenue Growth
- EXEL 10.73
- SIGA 3.86
- 52 Week Low
- EXEL $25.17
- SIGA $4.95
- 52 Week High
- EXEL $49.62
- SIGA $9.62
- Technical
- Relative Strength Index (RSI)
- EXEL 53.48
- SIGA 61.23
- Support Level
- EXEL $36.78
- SIGA $8.49
- Resistance Level
- EXEL $39.27
- SIGA $9.09
- Average True Range (ATR)
- EXEL 0.94
- SIGA 0.30
- MACD
- EXEL 0.31
- SIGA -0.01
- Stochastic Oscillator
- EXEL 91.45
- SIGA 83.51
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.